A
Asher
Founder
Biotech founder. Previously founded and scaled a VC-backed biomanufacturing company.
The Intelligent Clinic
Pre-launch. First protocol opens through vetted partner clinics in permitted jurisdictions.
Signal AIPhysician-led
hs-CRPIGF-1Bio-ageCortisolThe problem
Longevity medicine is guesswork, sold at a premium.
A patient pays forty thousand dollars a year. They get a panel, a supplement list and a confident opinion.
Nobody measures whether it worked.
The panel is read once. The protocol is copied from a conference stage. The outcome is never re-measured, so the clinic never learns anything.
1
protocol reused across every patient
0
feedback loops between therapy and outcome
0
longitudinal datasets being built
Aging is the largest market in medicine, and it is still being treated with intuition.
Every other field of medicine moved to measurement, feedback and evidence. Longevity never did.
Why now
Measurement got cheap. Models got good. The same year.
Multi-omic panels now cost a fraction of what they did five years ago, and models can finally read them.
$0B
Biomarker market by 2034
$0B
Longevity market by 2035
0%
AI in healthcare CAGR
0+
Jurisdictions now permitting
The window is open for one clinical platform to define the category.
Regulation in Florida and Japan already permits the therapies. The bottleneck is intelligence, not access.
The solution
We built the Signal Clock.
A clinical model that learns how fast a specific person is aging, then designs the protocol to slow it.
Signal ClockPace of aging
- 01
Measure
Labs, imaging, wearables and the Signal Visual Analyzer collapse into one living patient model.
- 02
Learn
The Signal Clock turns that model into a real pace of aging, updated every read.
- 03
Prescribe
Protocols are sequenced with exact dosing, timing gates and hold rules. A physician signs.
- 04
Verify
Week twelve re-reads prove what moved. Every outcome retrains the Clock.
The loop closes. That is the whole product.
Peptides, exosomes and geroprotectors are the delivery. The intelligence that decides what to give, when to escalate and when to stop is the company.
Physicians stay accountable for every decision.
The Clock proposes. A licensed physician reviews, signs and owns the protocol. That is what makes it a clinic instead of an app.
Business
Nobody owns the AI longevity clinic layer.
Labs sell tests. Clinics sell visits. Wearables sell scores. We own the loop between them, and the data it produces.
Three things compound.
Paired outcome data
Week zero and week twelve reads on every patient. Almost nobody has this.
Encoded protocol logic
Dosing, stacking and hold rules written down, reviewed and versioned.
Clinic network
Delivery inside licensed clinics in jurisdictions that already permit it.
A huge, fast-growing market.
TAM
$67B
Global longevity medicine
SAM
$8B
Physician-led premium programmes
SOM
$120M
Florida and Japan clinic network
How the clinic makes money.
Patient membership$4–12k per year
Clinic platform licenceSaaS per seat
Protocol deliveryRevenue share
Target ARPU of $7.5k, gross margin near seventy percent, payback under five months.
The raise
$1M
Pre-seed · 12-month runway
- 01
Ship Protocol 01 into Florida and Japan clinics
- 02
Onboard 500 patients with paired reads
- 03
Publish the first longitudinal outcome dataset
Team
Built by people who've done this before
T
Tal
Co-Founder
AI specialist with a background in Stanford bioinformatics.
D
Dr. Sandra
Co-Founder
Well-renowned longevity physician.
Early access
Be first when the protocol opens
Join the early access list and we'll notify you when enrollment opens for the first protocol.
No spam, no sharing your data. One email when we open.